Objective:To evaluate the efficacy and safety of moxifloxacin as well as levofloxacin in the treatment of multidrug resistance tuberculosis (MDR-TB) in China. Methods:Databases included the CB1Mdisc,CNKI,wangfang data,and VIP from Jan,2000 to Jun,2014 were retrospectively searched to collect randomized controlled trials (RCTs) of moxifloxacin and levofloxacin for MDR-TB. The methodological quality of included studies was evaluated,and data analyses were performed with The Cochrane Collaboration’s software RevMan 5.3.0. Results:A total of 36 RCTs were included. The results showed that,compared with the levofloxacin group,moxifloxacin increased the sputum negative conversion rate after 3-month taking(OR=2.25,95%CI:1.87~2.40)and at the end of the treatment period(OR=3.70,95%CI:2.97~4.62). Moxifloxacin was more effective in focus absorption(OR=2.45,95%CI:1.90~3.17),cavity closure(OR=1.82,95%CI:1.45~2.29)and clinical curative effect(OR=5.08,95%CI:3.58~7.22). However,there was no statistical difference in incidence of adverse reaction (P=0.14). Conclusion:According to the domestic evidence,moxifloxacin is more effective for MDR-TB than levofloxacin. Its adverse reaction rate is equivalent to levofloxacin.